Literature DB >> 15231024

Obsessive-compulsive symptoms with olanzapine.

Basil Alevizos, Charalambos Papageorgiou, George N Christodoulou.   

Abstract

The emergence or exacerbation of obsessive-compulsive (OC) symptoms during treatment with atypical antipsychotics, mostly clozapine, has been documented by numerous case reports (reviewed by Lykouras et al., 2003). In six recent reports involving nine cases, (Jonkers and de Haan, 2002; Lykouras et al., 2003) olanzapine was found either to cause de novo emergence or to exacerbate OC symptoms. In six of these cases olanzapine caused exacerbation and in three cases caused de novo emergence of OC symptoms.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15231024     DOI: 10.1017/S1461145704004456

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  4 in total

Review 1.  Second generation antipsychotic-induced obsessive-compulsive symptoms in schizophrenia: a review of the experimental literature.

Authors:  Trehani M Fonseka; Margaret A Richter; Daniel J Müller
Journal:  Curr Psychiatry Rep       Date:  2014-11       Impact factor: 5.285

2.  Obsessive-Compulsive Disorder, Psychosis, and Bipolarity: A Longitudinal Cohort and Multigenerational Family Study.

Authors:  Martin Cederlöf; Paul Lichtenstein; Henrik Larsson; Marcus Boman; Christian Rück; Mikael Landén; David Mataix-Cols
Journal:  Schizophr Bull       Date:  2014-12-15       Impact factor: 9.306

3.  Olanzapine induced de-novo obsessive compulsive disorder in a patient with schizophrenia.

Authors:  Gajanan Kulkarni; Janardhanan C Narayanaswamy; Suresh Bada Math
Journal:  Indian J Pharmacol       Date:  2012 Sep-Oct       Impact factor: 1.200

4.  Obsessive-compulsive disorder comorbidity: clinical assessment and therapeutic implications.

Authors:  Stefano Pallanti; Giacomo Grassi; Elisa Dinah Sarrecchia; Andrea Cantisani; Matteo Pellegrini
Journal:  Front Psychiatry       Date:  2011-12-21       Impact factor: 4.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.